Bruno Anthony D 4
4 · Menlo Therapeutics Inc. · Filed Apr 7, 2020
Insider Transaction Report
Form 4
Bruno Anthony D
Director
Transactions
- Award
Common Stock
2020-04-03+14,933→ 135,056 total - Award
Common Stock
2020-04-03+75,690→ 120,123 total
Footnotes (3)
- [F1]As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)
- [F2](continued from footnote 1) awards that were received by the reporting person as a result of the foregoing.
- [F3]Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo.